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Summary
The purpose was to apply oxidative crosslinking reac-
tions to the study of recognition and signaling mech-
anisms associated to G-protein-coupled receptors.
Using a ruthenium chelate, Ru(bipy)32+, as photosen-
sitizer and visible light irradiation, in the presence of
ammonium persulfate, we performed fast and efficient
covalent labeling of the B2 bradykinin receptor by ago-
nist or antagonist ligands possessing a radio-iodinated
phenol moiety. The chemical and topographical specifi-
cities of these crosslinking experiments were investi-
gated. The strategy could also be applied to the cova-
lent labeling of the B1 bradykinin receptor, the AT1
angiotensin II receptor, the V1a vasopressin receptor
and the oxytocin receptor. Interestingly, we demon-
strated the possibility to covalently label the AT1 and
B2 receptors with functionalized ligands. The poten-
tial applications of metal-chelate chemistry to recep-
tor structural and signaling studies through intramo-
lecular or intermolecular crosslinking are presented.
Introduction
The fast development of structural and proteomic ap-
proaches in the study of signaling mechanisms requires
a panel of methods for the study of biological recogni-
tion processes. In this respect, biochemical strategies
constitute powerful tools. They are currently applied in
the field of G-protein-coupled receptors (GPCRs), to
the topographical analysis of the receptor itself [1] or
its interactions with protein partners [2–4].
The purpose of the present work was to extend the
panoply of available crosslinking strategies by going
deeply into previously reported chemistry [5–10] and*Correspondence: jcbonnaf@montp.inserm.fr
3 These authors contributed equally to this work.proposing new applications in the field of ligand-recep-
tor interaction investigations.
Specific covalent labeling of receptors with photoac-
tivable hormone derivatives has been extensively used
for characterization and mapping purposes. Many of
these studies involved compounds possessing azido or
benzophenone moieties which require UV irradiation for
photoactivation and are often lacking specificity in their
reactions with protein chemical functions. An alterna-
tive is based on ligand crosslinking to its receptor using
homo- or hetero-bifunctional reagents. In spite of ef-
forts devoted to the development of covalent labeling
of the bradykinin B2 receptor [11–13], no high yield la-
beling strategy is presently available. We decided to
use a strategy previously applied to oxidative protein-pro-
tein crosslinking, using photosensitization by a ruthe-
nium derivative, Ru(bipy)32+ in the presence of ammo-
nium persulfate (APS) [9, 10]: the underlying chemistry
was proposed to involve the formation of radicals al-
lowing tyrosine residues to give covalent bonds with
another tyrosine or with a cysteine [9, 10]. Starting from
this mechanistic proposal, we tried to photolabel the
human B2 bradykinin receptor with ligands possessing
a radioiodinated phenol moiety at their N termini,
[125I]HPP-HOE 140 (radioiodinated hydroxyphenyl-pro-
pionyl-HOE 140) and [125I]Tyr0-BK, which behave as in-
verse agonist and agonist, respectively. The present
work demonstrates that this strategy allows receptor
photolabeling with a high yield and very short reaction
times. We also endeavored to extend the method to
other GPCRs belonging to the same subfamily (B1
bradykinin, AT1 angiotensin II receptors) or to the vaso-
pressin/oxytocin receptor subfamily. The chemical and
topographical specificities of the involved chemical re-
actions were investigated. The potential applications of
the described strategies to topographical and signaling
mechanism studies are presented; some of them take
advantage of the very short reaction times required for
efficient oxidative crosslinking photosensitized by ru-
thenium compounds.
Results
Receptor photolabeling using ligands possessing a ra-
dio-iodinated phenol was first carried out on the B2 re-
ceptor. The work includes a rather exhaustive descrip-
tion of this pilot study. Then the strategy was extended
to other receptor/ligand couples which are listed in Fig-
ure 1.
Ru(bipy)32+ Photosensitized Covalent Labeling
of the B2 Receptor
Characterization of Covalently Labeled Receptor
COS-7 cells expressing the human B2 receptor were
incubated at 4°C with nanomolar concentrations of
either the antagonist [125I]HPP-HOE 140, which in fact
behaved as an inverse agonist [14], or the agonist
[125I]Tyr0-BK. After removal of the medium containing
the radioligand, the dishes were supplemented with
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16Figure 1. Structure of Synthetic Ligands Adapted to the Ru(bipy)32+ Photosensitized Crosslinking of GPCRsPBS medium containing Ru(bipy)32+ (concentration range b
p0–2 mM) and ammonium persulfate (APS, concentration
range 0-0.5 mM), then irradiated for short times (3-30 s) t
nby a visible light source. Analyses of the SDS-solubi-
lized cell samples showed labeling of a 76 kDa entity s
by both the antagonist (Figure 2A) and the agonist (Fig-
ure 2B). The rather heterogeneous aspect of this band w
oand its molecular mass are those expected for intact
receptor and the specificity of the labeling was as- b
sessed by its suppression when an excess of unlabeled
ligands was present in the initial phase of receptor site m
asaturation (Figure 2). No labeling was detected when the
ruthenium derivative, or APS, or irradiation were omit- f
ited, as well as in nontransfected COS-7 cells (Figure
2A). Receptor labeling was also carried out on mem- r
sbrane preparations from COS-7 cells, with similar effi-
ciency as in intact cells (not shown). As the B2 receptor k
tpossesses a c-Myc tag at its N terminus, solubilized
membranes from photolabeled cells were analyzed by i
1SDS-PAGE and then transferred to nitrocellulose mem-
branes: the major band detected by immunoblotting d
ausing anti c-Myc antibodies corresponded to the major
radioactive photolabeled species (Figure 2A). The 40 c
[kDa band probably represents immature receptor lack-
ing glycosidic chains which has not reached the plasma t
tmembrane and is unable to bind ligands [15].
The minor labeled form, centered at 50 kDa in the w
cautoradiograms, probably represents partially deglyco-
sylated entities as its amount was independent from m
airradiation time and the presence of protease inhibitors.
The differences between the patterns of these minor pands in immunoblots and autoradiograms is not sur-
rising; if antibodies should recognize immature recep-
ors which are unaccessible to ligand binding, one can-
ot rule out the possible proteolytic loss of the tag
equence.
Some labeling, possibly representing aggregates,
as also detected at high molecular weights on the top
f the gels: it was dependent upon the irradiation time,
eing negligible at 3 s.
The yields of [125I]HPP-HOE 140 photolabeling, esti-
ated from radioactivities associated with the 76 kDa
nd 50 kDa entities in SDS-PAGE gels, were 18%–25%
or irradiation times as short as 3 s and slightly
ncreased up to 30% when irradiation lasted 30 s. The
adioactivities associated with the 76 kDa band were
ystematically found to be two times greater than 50
Da radioactivity, irrespective of reaction times and Ru-
henium chelate/APS concentrations. High photolabel-
ng yields were also obtained for [125I]Tyr0-BK (16% and
8% for 3 and 30 s irradiation times, respectively). These
eterminations were in agreement with measurements of
cid-wash-resistant radioactivities representing spe-
ific covalent association to intact cells : 24%–30% for
125I]HPP-HOE 140 photolabeling (3–30 s irradiation
imes) and 21%–25% for [125I]Tyr0-BK photolabeling;
he slightly higher values obtained using this protocol
ere probably due to the fact that they take into ac-
ount all the photolabeled species, including the high
olecular weight entities which are most often found
t the top of electrophoresis gels; nevertheless they re-
resent actual efficiencies of the photochemical pro-
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17Figure 2. Photolabeling of the B2 Bradykinin Receptor in Intact Cells by [125I]HPP-HOE 140 and [125I]Tyr0-BK Using Ru(bipy)32+ and APS
The B2 receptor was transiently expressed in COS-7 cells, at a density of 5 × 105 sites/cell. Equilibrium binding of [125I]HPP-HOE 140 (2 nM)
or [125I]Tyr0-BK (8 nM) to intact cells, and photolabeling using Ru(bipy)32+ (0.5 mM) and APS (0.5 mM) were carried out as described in
Experimental Procedures, using the indicated irradiation times.
(A) Left panel, antagonist photolabeling. Lanes d–f, [125I]HPP-HOE 140 labeling. No receptor labeling was detected when Ru(bipy)32+ (b) or
APS (c) were omitted or when an excess of unlabeled HPP-HOE 140 (g) or HOE 140 (h) was present in the initial step of receptor site
saturation. No labeling was observed in control nontransfected COS-7 cells (lane i). Lanes j and k, protein staining of solubilized irradiated (3 s) or
nonirradiated cells corresponding to assays a and d. Lanes l, m, and n, solubilized membranes from photolabeled cells were submitted to
SDS-PAGE, transfered onto nitrocellulose membranes before analysis by immunoblotting using an anti-c-Myc antibody. The figure represents
a typical experiment, representative of five separate experiments.
Right panel, incidence of irradiation conditions on ligand binding properties. COS-7 cells transiently expressing the B2 receptor were incu-
bated for 3 hr at 4°C in the absence or presence of 5 nM unlabeled BK, HPP-HOE 140, or HOE 140. After removal of unbound ligand and
rapid washing, the cells were irradiated for 3 s in the presence of Ru(bipy)32+/APS. Membranes were then prepared from these cells, and
submitted to a ligand dissociation treatment consisting of a 30 min incubation at room temperature followed by centrifugation. The binding
of [125I]HPP-HOE 140 to membrane preparations was checked as described in Experimental Procedures. A, membranes from cells irradiated
without receptor occupancy. B, membranes from cells irradiated after receptor occupancy by BK. C, membranes from cells irradiated after
HPP-HOE 140 receptor occupancy. D, membranes from HOE 140 occupied receptor. The incomplete recovery of binding sites in the D section
probably results from incomplete HOE 140 dissociation as compared to other checked ligands. The Figure represents a set of data obtained
within the same experiment, each binding determination being carried out in triplicate. Similar results were reproduced twice.
(B) Agonist photolabeling. Lanes b and c, [125I]Tyr0-BK labeling. No receptor labeling was detected in the absence of irradiation (lane a) or
when an excess of unlabeled BK (lane c) or Tyr0-BK (lane d) was present in the initial step of receptor site saturation. Negligible crosslinking
was observed when cells were irradiated after saturation with [125I](Tyr8)-BK (2 nM) without and with an excess of unlabeled ligand (lanes e
and f) or with [125I]Lys0-(Tyr8)-BK (16 nM) without and with an excess of unlabeled ligand (lanes g and h). The figure represents a typical
experiment representative of three separate experiments. The indicated yields represent the mean of at least three experiments, and relative
variations between experiments never exceed 10%.cedure. These values were also corroborated by the de-
tailed analysis of the binding properties of membranes
prepared from photolabeled cells (see Figure 2 and re-
lated paragraph in the text).
Chemistry and Topographical Requirements
of Covalent Labeling
A strong indication of the chemical and topographical
specificities of the B2 receptor photolabeling was the
possibility of keeping excess free ligand up to 2 nM
concentrations during the irradiation phase without la-
beling proteins other than the receptor (not shown).The presence of a phenol moiety at the ligand N-ter-
minal ends was required for efficient covalent labeling.
[125I](Tyr8)-BK and [125I]Lys0-(Tyr8)-BK, which display
agonist properties, could not be significantly cross-
linked to the receptor (Figure 2B). These negative re-
sults imply that their N-terminal amino group (and the
amino group of the lysine side-chain of [125I]Lys0-(Tyr8)-
BK) does not participate in receptor labeling, in
agreement with the failure of lysine to inhibit ligand
crosslinking. They do indicate that [125I]Tyr0-BK cross-
linking involves its phenol moiety. That [125I]HPP-HOE
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18140 crosslinking involves its phenol moiety was corrob- B
Worated by other experiments (see next section and Fig-
ure 2A). b
sPreservation of Receptor Binding and Signal
Transduction Properties upon a
iPhotochemical Treatment
Taking into account the rapidity and diversity of chemi- B
ical reactions catalyzed by the ruthenium chelate/APS/
hν system, it appeared necessary to verify that unde- r
sired reactions accompanying ligand crosslinking to
the receptor do not essentially perturb the pharmaco- [
elogical behavior of the system. COS-7 cells expressing
B2 receptors were submitted to irradiation treatment, r
[with or without previous saturation of the binding sites
by BK, HOE 140, or its crosslinkable analog HPP-HOE t
140 (Figure 2A). When the cells were preirradiated in the
presence of ruthenium chelate/APS without any ligand, c
tsubsequent binding of [3H]BK and [125I]HPP-HOE 140
to membrane preparations was significantly impaired o
t(30% decrease in binding capacities for 3 s irradiation
time, with no significant changes in affinity). The minimal V
Ttreatment (3 s irradiation, 0.5 mM ruthenium chelate, 0.5
mM APS) of cells expressing moderate receptor amounts c
s(105 sites/cell) induced about 30% decreases in the
basal and BK-stimulated IP accumulation, consistent (
rwith the above mentioned loss of binding sites (not
shown). Although one cannot exclude a possible desta- p
ibilization of receptor structure, the slight loss of binding
sites upon irradiation of unoccupied receptor might re- m
osult from intramolecular receptor crosslinking which
would cause limited accessibility for ligand binding. w
uInterestingly, ligand occupation of cell binding sites
upon irradiation exerted a protective effect. Membrane [
preparations from liganded irradiated cells were washed
so as to dissociate noncovalently bound ligand and E
checked for their ability to rebind [125I]HPP-HOE 140. Irra- P
diation of cells in the presence of BK induced no change A
in subsequent binding of the radioiodinated ligand to c
membrane preparations as compared to control non- a
irradiated cells (Figure 2A). As expected, irradiation of s
cells previously incubated with unlabeled crosslinkable r
HPP-HOE 140 induced a decrease in subsequent li- s
gand binding to membrane preparations, consistent p
with the photolabeling yields determined from electro-
phoresis gels. No irradiation-induced decrease was ob- f
served for cells previously saturated with unmodified b
HOE 140, confirming that the phenol moiety of HPP-HOE d
140 is required for ligand crosslinking; the difference c
observed between nonirradiated cells previously satu- N
rated with HOE 140 and HPP-HOE 140 should result (
from incomplete dissociation of the former ligand from t
the corresponding membrane preparations before the o
ffinal radioligand binding. One can conclude that the
iphotolabeling treatment has no overall deleterious ef-
vfect and that the strategy is suitable for future struc-
ptural investigations.
c
t
Extension of the Ru(bipy)32+ Photosensitized
Crosslinking Strategy to Other Receptors D
We took advantage of the availability of phenolated li-
gands designed for radioiodination to extend the strat- T
tegy to other GPCRs.1 and AT1 Receptors
e checked the possibility of performing covalent la-
eling of the AT1 and B1 receptors that belong to the
ame subfamily as the B2 receptor, using respectively
s ligands [125I]Tyr0-AII (which also possesses a Tyr res-
due at its position 4) and [125I]JMV 1109, a synthetic
1 receptor ligand which possesses a phenol moiety at
ts N terminus (Figure 1) and sufficient affinity for the
eceptor (Kd value of about 10 nM).
Figure 3 shows an efficient and rapid crosslinking of
125I]Tyr0-AII to the AT1 receptor, thus providing an inter-
sting alternative to the use of azido-phenylalanine de-
ivatives [16, 17]. Much lower yields were obtained with
125I](Sar1)-AII (1% and 4% for 3 and 30 s irradiation
imes, respectively).
Interestingly, the human B1 receptor photolabeling
ould also be achieved (Figure 3), with a quite satisfac-
ory yield (10%–12%). These experiments constitute, to
ur knowledge, the first reported covalent labeling of
his receptor.
asopressin and Oxytocin Receptors
he V1avasopressin receptor and the oxytocin receptor
ould also be efficiently labeled by their radioiodinated
pecific ligands, [125I]HO-LVA and [125I]OTA, respectively
Figures 1 and 3), the ability of [125I]OTA to label both
eceptors being consistent with previously established
harmacological properties [18]. The labeling patterns,
ncluding the visualization of receptor proteolytic frag-
ents, are quite superimposable to those previously
btained upon photolabeling by azido-derivatives which
ere shown to react with amino acids located in the
pper parts of TM3, TM7, and the first extracellular loop
19, 20].
xtension of the Crosslinking Strategy to Receptor
hotolabeling with Functionalized Ligands
pplications of receptor covalent labeling should in-
lude receptor purification for structural studies and
dsorption of covalent ligand-receptor complexes to
pecific matrices for 2D crystallization (Figure 6). In this
espect, it will be worth testing the possibility of ad-
orption of Gly-Gly-His-tagged ligand-receptor com-
lexes to Ni2+ chelating supports.
These applications require receptor labeling with
unctionalized ligands. The B2 could be photolabeled
y the ligand L13 possessing, in addition to a Tyr resi-
ue, a biotin at its N terminus. The B2 and AT1 receptors
ould also be efficiently labeled by ligands L12 and L11,
-terminally extended by the Gly-Gly-His-Tyr sequence
Figures 1 and 4) and displaying fairly preserved affini-
ies (Kd values in the nanomolar range). The presence
f this sequence at the ligand extremity should be help-
ul to target crosslinking to the ligand vicinity (possibly
ncluding ligand crosslinking itself), when required. We
erified that the Gly-Gly-His/Ni2+ chelate [6–9], in the
resence of magnesium monoperoxyphthalate (MMPP),
ould catalyze [125I]HPP-HOE 140 covalent labeling of
he B2 receptor (8%–10% yield) (Figure 4).
iscussion
he present work constitutes an innovating alternative
o existing strategies for GPCR covalent labeling by
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19Figure 3. Extension of the Photolabeling
Strategy to Other Receptors
(A) B1 and AT1 receptors HEK 293 or COS-7
cells, transiently expressing the B2 or B1
bradykinin receptors, or the AT1 angiotensin
II receptor, were saturated by their respec-
tive radioiodinated ligands [125I]HPP-HOE 140,
[125I]JMV 1109, [125I]Tyr0-AII, and [125I](Sar1)-
AII. After removal of unbound ligand and
rapid washing, the cells were irradiated for
3 s in the presence of Ru(bipy)32+/APS. Cells
were solubilized in electrophoresis sample
buffer and analyzed by SDS-PAGE and auto-
radiography. Lanes a and b, photolabeling of
B2 receptor expressed HEK 293 cells (50 ×
103 sites/cell, 1.8 × 106cells/well), after site
saturation with [125I]HPP-HOE 140 (2 nM) in
the absence or presence of excess unla-
beled ligand; notice that the B2 receptor dis-
plays a decreased extent of glycosylation as
compared to receptor expressed in COS-7
cells. Lanes c and d, photolabeling of the B1
receptor transiently expressed in HEK 293
cells (40 × 103 sites/cell, 1.5 × 106 cells/well),
an expression level higher than those rou-
tinely found in COS-7 cells [38], after site
saturation with [125I]JMV 1109 (10 nM) in the
absence or presence of excess unlabeled li
gand. Lanes e and f, photolabeling of the AT1 receptor expressed in COS-7 cells, after site saturation with [125I]Tyr0-AII (3 nM). Lanes g and
h, photolabeling of the AT1 receptor expressed in COS-7 cells, after site saturation with [125I](Sar1)-AII (2 nM) in the absence or presence of
excess unlabeled ligand.
(B) Vasopressin and ocytocin receptors. The human V1a vasopressin and ocytocin receptors, stably expressed in CHO cells (expression levels:
3–4 × 105 and 1–1.5 × 105 sites/cell, respectively) were saturated by [125I]HO-LVA (0.5 nM) or [125I]OTA (0.5 nM and 3 nM for V1a and ocytocin
receptors, respectively). After removal of unbound ligand and rapid washing, the cells were irradiated for 5 s in the presence of Ru(bipy)32+/
APS. Cells were solubilized in electrophoresis sample buffer and analyzed by SDS-PAGE and autoradiography. Lanes a and b, V1a receptor
labeling by [125I]HO-LVA, in the absence or presence of excess unlabeled ligand. Lanes c and d, V1a receptor labeling by [125I]OTA in the
absence or presence of excess unlabeled ligand. Lanes e and f, OT receptor labeling by [125I]OTA in the absence or presence of excess
unlabeled ligand. As detailed for the B2 receptor ligands (Figure 2), no labeling was observed with any of the ligands on control nontransfected
cells. Receptor labeling was suppressed when irradiation was omitted (not shown). The indicated yields represent the mean of at least three
experiments, and relative variations between experiments never exceed 10%.specific ligands. Several receptors of the family could
be photolabeled, in intact cells, by ligands possessing
a radioiodinated phenol moiety, using Ru(bipy)32+ in the
presence of APS. The labeling yields were at least as
high as those obtained using other methods, most
often involving azido-derivatives [16, 17, 19, 20], with a
substantial advantage in terms of reaction time course.
Concerning the B2 receptor which we studied in more
detail, previous BK or analog crosslinking studies were
carried out using classical bifunctional agents [11–13];
however, the labeling yields were only assessed by in-
direct evidence and the experimental protocols recently
used for the characterization of B2 receptor dimeric
structures [21, 22] suggest rather low efficiencies. A
requirement for the high efficiency of the ruthenium
chelate/APS/hν procedure appears to be the localiza-
tion of the ligand phenol moieties in the receptor extra-
cellular loops or upper parts of transmembrane do-
mains, which ensure their accessibility to the reagents
which cannot penetrate into the cells. The pharmacol-
ogy of the used ligands and previous mapping studies
of the various receptors [11, 13, 19, 20] are consistent
with this assumption; the much lower efficiencies in the
crosslinking of [125I](Tyr8)-BK and [125I](Sar1)-AII to their
respective receptors probably results from a more bur-
ied position of their Tyr residues in the receptor binding
site [11–13, 23], although the lack of neighboring react-
ing partner might provide an alternative explanation.The chemical mechanism of the ligand phenol reticu-
lation to the receptor deserves a comment: it has been
postulated that radical formation at ortho positions of
the hydroxyl group are primarily involved in crosslinking
reactions (Figure 5), without excluding alternative pos-
sibilities [9, 10]. Our data report attempts to crosslink a
phenol moiety possessing an iodine atom at an ortho
position of the hydroxyl group: obviously, this iodine
does not inhibit the crosslinking reaction and is not
eliminated. Moreover we showed that the diiodinated
compounds [125I2]Tyr0-BK and [125I2]HPP-HOE 140 could
be crosslinked to the receptor with unchanged yields as
compared to the monoiodinated compounds (not
shown). It indicates that, as previously emphasized [9],
the chemistry of phenol crosslinking is not exhaustively
understood (Figure 5).
The most likely receptor candidates for crosslinking
to phenolated ligands (Figure 5B) appear to be Tyr, Cys,
and Trp residues and the extracellular disulfide bridge(s).
It was suggested by their ability to reverse the B2 re-
ceptor photolabeling by [125I]HPP-HOE 140 (which
does not constitute a proof by itself [9]), by previous
mechanistic studies relative to metal chelates [9, 10] or
heme enzymes [24–28], and by recent data emphasiz-
ing cystine reactivity [29]. Preliminary experiments de-
signed to investigate the role of extracellular Tyr resi-
dues (B2 receptor mutated at Tyr174 and Tyr188, V1a
receptor mutated at Tyr115) were unsuccessful; how-
Chemistry & Biology
20Figure 4. Photolabeling of AT1 and B2 Receptors by Functionalized Ligands
(A and B) The B2 (A) and AT1 (B) receptors, transiently expressed in COS-7 cells, were photolabeled for 5 s by the parent-specific ligands
(L10: 0.4 nM; L7: 1.8 nM) or ligands possessing either a biotin (L13: 0.4 nM), or a GGH sequence (L11: 0.3 nM and L12: 1.8 nM) at their N termini,
in the presence of Ru(bipy)32+/APS as described in the Experimental Procedures. Lanes b, d, and f, presence of an excess of unlabeled ligand.
(C) B2 receptor labeling by [125I]HPP-HOE 140 in the presence (lane a) or absence (lane c) of 5 mM GGH/Ni2+ complex and 5 mM MMPP
(reaction time 1 min). Lane b, presence of excess unlabeled ligand during site saturation. The indicated yields represent the mean of at least
three experiments, and relative variations between experiments never exceed 10%.ever, one cannot rule out possible compensatory mech- p
manisms allowed by the multiplicity of chemical reactions
and receptor loop flexibility. Future compared mapping s
tstudies of these receptors and determination of cross-
linked receptor fragments by mass spectrometry should c
tbring informations about the involved chemical reac-
tions. Interestingly, they should help to understand the t
role of extracellular domains in GPCR ligand recogni-
tion and activation or inactivation processes. Such a p
srole for the second extracellular loop in rhodopsin acti-
vation has recently been shown [30]. i
tMore generally the diversity and complexity of elec-
tron transfer reactions and generation of protein radi- t
scals is emphasized by the mechanism of action of heme
enzymes [24]. Crosslinking reactions described in the c
Kpresent work obviously depend on fortuitous proximity
between a ligand phenol and selected receptor amino s
Gacids. An essential point is that the diversity of appro-
priate electronic environments is not inconsistent with c
dthe specificity of the labeling of each receptor of inter-
est, with negligible random reactions and no overall s
sdeleterious modifications of the signal transduction
system. The diversity of possible chemical reactions f
aprobably explains the successful examples reported in
this paper and allows us to predict applications to other i
csignal transduction systems.
The ruthenium chelate photosensitized reactions should a
salso be extended to intramolecular crosslinking between
specific amino acids of wild-type or mutant receptors lossessing Tyr, Cys, or Trp at appropriate locations; it
ight allow the stabilization of selective conformational
tates and thus be helpful for mechanistic and struc-
ural studies (Figure 6). Stabilization of rhodopsin extra-
ellular domain through a salt bridge [31] or an addi-
ional disulfide bridge [32] underlines the interest of
his goal.
Receptor photolabeling by functionalized ligands
ossessing a biotin or a Gly-Gly-His sequence, re-
tricted at this stage to the AT1 and B2 receptors, open
nteresting applications such as receptor purification,
argeted crosslinking in the ligand vicinity, and adsorp-
ion of covalent ligand-receptor complexes or larger
upramolecular complexes to specific matrices for 2D
rystallization (Figure 6). The initial goal proposed by
odadek’s group, i.e., protein-protein crosslinking [10],
hould be a matter of interesting applications in the
PCR field (Figure 6); studies dealing with receptor-
ofactor interactions and receptor homo- or hetero-
imerization should take advantage of crosslinking
trategies involving chemical reactions which display
pecificities other than those allowed by classical bi-
unctional agents or photolabels. The various structural
pplications will require taking into account the local-
zation of desired crosslinking sites, the diffusion and
ell penetration properties of metal chelates, and their
ction radius in terms of electronic transfer. In this re-
pect, the possibility of using the Gly-Gly-His/Ni2+ che-
ate [7] is liable to extend the applications. When neces-
Ruthenium Photosensitized Receptor Labeling
21Figure 5. Putative Reactions and Crosslinking Sites Involved in Receptor Photolabeling
The common structural feature of the ligands which can be efficiently crosslinked to the various GPCRs is the presence of a parahydroxyben-
zyl group radio-iodinated at one of its ortho positions for routine experiments (A). The presence of a second iodine atom does not prevent
crosslinking and the iodine atoms do not appear to be eliminated during the Ru(bipy)32+/APS catalyzed reaction, indicating that the reactions
are not restricted to the phenol ortho positions which have been suggested to be primarily involved [9, 10]. A detailed chemical study would
be required to determine the effects of iodine atoms on the preferential generation of free radicals on the various positions.
(B) Effect of various amino-acids on B2 receptor photolabeling by [125I]HPP-HOE 140 using the Ru(bipy)32+/APS system: The B2 receptor
transiently expressed in COS-7 cells was photolabeled as described in the legend of Figure 2 and Experimental Procedures. Various amino
acids were added, at the indicated concentrations, to the Ru(bipy)32+/APS containing medium immediately before irradiation (5 s). Results
are expressed as % of photolabeling yield without any added amino acid. The figure represents a typical experiment representative of three
separate experiments.
(C) Location of Tyr, Cys, and Trp residues in the GPCR extracellular domains or upper part of the TMs, as candidates to ligand crosslinking
photosensitized by extracellularly added ruthenium chelate. The candidates to ligand crosslinking in the B2 receptor are Tyr174, Tyr188, Trp25,
Trp28, Trp96, Trp193, the conserved Cys103-Cys184 disulfide, Cys20, and Cys277 (possibly disulfide linked).sary, the crucial problem of accessibility might be
solved by replacing Ru(bipy)32+ by metallic porphyrin
derivatives [33] and APS by permeant oxidizing agents.
Finally, the short duration times allowed by the pho-
tochemistry of ruthenium compounds should give rise
to applications in cell biology, for instance kinetic
studies of signaling cascades, and thus help to better
understand the dynamic aspects of scaffoldings in
these pathways.
Significance
The present work reports, to our knowledge, the first
applications of Ru(bipy)32+ photosensitized reactions,
previously initiated for protein-protein crosslinking
[10], to the covalent labeling of GPCRs by appropriate
ligands possessing a radioiodinated phenol. Based
on a more extensive study of B receptor labeling by2agonist and antagonist ligands, which constitutes by
itself a significant progress, we performed a covalent
labeling of the B1 bradykinin receptor and proposed
the same strategy for the photolabeling of the AT1 an-
giotensin II receptor, the V1a vasopressin receptor,
and the oxytocin receptor. The pharmacology of the
used ligands, previous mapping studies of the vari-
ous receptors [11, 13, 19, 20], and the likely difficulty
of the ruthenium chelate to penetrate inside the cells,
point to crosslinking sites located in the extracellular
loops or the upper part of the transmembrane do-
mains and probably involving Tyr, Cys, or Trp resi-
dues. Such crosslinkings, which display specificities
other than those allowed by classical bifunctional
agents or photolabels, is expected to stabilize recep-
tors for structural studies and might be completed by
additional intramolecular or intermolecular cross-
linking. Protein-protein crosslinking should be a
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Crosslinking to GPCR Structural and Signal-
ing Mechanism Studies
The photolabeling of several GPCRs with li-
gands possessing a phenol moiety probably
involves the extracellular loops or the upper
parts of the TMs, taking into account the lack
of penetration of the reagents Ru(bipy)32+ and
APS. Future mapping studies will allow char-
acterization of the receptor crosslinking sites.
Stabilization of specific receptor conforma-
tional states through covalent binding can be
expected, and might be completed by addi-
tional intramolecular crosslinking, using ap-
propriate mutagenesis. The interest of this
kind of biochemical engineering is empha-
sized by growing evidence for a concerted
role of extracellular loops and transmem-
brane domains in GPCR activation. Intermo-
lecular crosslinking might also occur be-
tween the receptor and interacting partners. The possibility of applying crosslinking to functionalized ligands should open the way to the
purification of covalent ligand-receptor complexes or larger supramolecular edifices, as well as targeted crosslinking or adsorption to derivat-
ized surfaces for structural studies.tmatter of interesting applications in the GPCR field;
ostudies dealing with receptor-cofactor and receptor
[homo- or heterodimerization should benefit from
c
these new crosslinking strategies. The chemical de- c
sign of fonctionalized crosslinkable ligands open inter- c
mesting applications for the structural analysis of ligand-
areceptor complexes, or larger supramolecular edi-
fices. The short reaction times required for ruthenium
Cchelate photolabeling should allow kinetic studies of
C
signaling pathways, thus extending biochemical ap- i
proaches to cell biology. They might be associated r
with alternative oxidative crosslinking strategies s
susing the Gly-Gly-His/Ni2+ chelate or porphyrins, and
7be applied to other signal transduction systems for
Iassessing their general usefulness in molecular phar-
i
macology. d
c
Experimental Procedures P
a
Reagents and Ligands s
BK, Tyr0-BK, (Tyr8)-BK, Lys0-(Tyr8)-BK, and AII were purchased from m
Sigma, myo-[2-3H]inositol and [3H]BK (specific radioactivity about w
100 Ci/mmol) from Amersham Pharmacia Biotech, and Ru(bipy)32+ r
from Aldrich. The radioiodinatable B2 receptor antagonist hydroxy- w
phenyl-propionyl-HOE 140 (HPP-HOE 140) and B1 receptor antago- s
nist JMV 1109 (hydroxyphenyl-propionyl-Lys-Arg-Pro-Hyp-Gly-Thi- t
Ser-D-Tic-Oic) were kindly supplied by Professor J. Martinez (CNRS, f
Montpellier, France). Tyr0-AII, Tyr0-BK and related functionalized
derivatives were synthesized by solid phase strategy, essentially as r
described in [34] with preoxidation of biotin to its sulfone derivative t
[35], the vasopressin and ocytocin receptor ligands synthesized as a
in [18]. The radioiodinated peptidic ligands (mono- or di-iodo deriv- l
atives) were prepared using Na125I and iodogen as oxidizing agent. a
COS-7, CHO cells and HEK 293 cells were from the European Cell o
Type Collection (Salisbury, United Kingdom). Anti c-Myc antibodies e
were from B. Mouillac. i
a
pReceptor Expression
mThe human B2 receptor sequence has been determined by Hess et
lal. [36]. The WT or mutant receptors were systematically tagged
through the addition of a 10 amino acid epitope (EQKLISEEDL)
from the c-Myc oncogene at their N termini truncated at the Asn3 L
Mresidue [14, 37]. The cDNA encoding the human B1 receptor was
subcloned in the pcDNA3 vector [14]. The AT1 receptor sequence r
wencoded a receptor possessing a c-Myc epitope at the N and Cermini as in [15]. Receptors were transiently expressed in COS-7
r HEK 293 cells using the electroporation transfection method
14]. The V1a and oxytocin receptors were stably expressed in CHO
ells (4–5 × 105 and 1–2 × 105 sites/cell respectively). Receptor
haracterization and crosslinking experiments were performed on
ells cultured for 2 days at 37°C in Dulbecco’s modified Eagle’s
edium, 4.5 g/l glucose, 10% fetal calf serum, 100 U/ml penicillin,
nd 100 U/ml streptomycin.
rosslinking Experiments
rosslinking experiments were routinely carried out on intact cells
n 24-well plates. Ligand binding to intact cells expressing the B2
eceptor was carried out at 4°C in Dulbecco’s phosphate-buffered
aline supplemented with 140 g/ml bacitracin, 1 mg/ml bovine
erum albumin, 1 mM o-phenanthroline and 10−5 M captopril (pH
.0), using a 3 hr incubation time, under gentle agitation [14, 37].
ncubation media used for the other receptors are those described
n [19, 20, 23, 38]. The binding medium containing excess radioio-
inated ligand was discarded and the cells were washed with ice-
old phosphate-buffered saline containing Ca2+ and Mg2+ (PBS).
hotolabeling in the presence of ruthenium chelate was carried out
s follows: under red light, the cell wells were added with PBS
upplemented with cold Ru(bipy)32+ (0–2.5 mM) and APS (0–0.5
M), then irradiated for 3–30 s, at 0°C, by visible light (two 100
att tungsten lamps, located 15 cm from the samples, and sepa-
ated from these latter by a water filter). The irradiation medium
as removed and the cells were solubilized in 150 l electrophore-
is sample buffer (containing mercaptoethanol which stops any fur-
her crosslinking) and containing or not a protease inhibitor cocktail
rom Sigma (2.5 l). The samples were sonicated before analysis.
The yields of covalent labeling were estimated by comparing the
adioactivities associated to receptor bands in electrophoresis gels
o the radioactivities representing specific binding of the ligand to
n equivalent cell sample, measured immediately before the cross-
inking step (systematic evaluation of total and nonspecific binding,
nd electophoretic control of samples from nonirradiated cells). The
btained values were in close agreement with those obtained by
valuation of radioactivities specifically (difference between bind-
ng in the absence or presence of excess unlabeled ligand) associ-
ted to cells after crosslinking followed by one PBS washing (in the
resence of 2 mM tyrosine) and three 15–30 s acid washings (150
M NaCl, AcOH 50 mM [pH 3]) to dissociate noncovalently bound
igand.
igand Binding to Membranes
embranes from COS-7 cells (100 g in 1 ml) expressing the B2
eceptor, prepared as described previously [14] were incubated
ith ligands for 1.5 hr at 25°C in 25 mM TES (pH 6.8), 140 g/ml
Ruthenium Photosensitized Receptor Labeling
23bacitracin, 1 mg/ml BSA, and 1 mM o-phenanthrolin added with a
protease inhibitor cocktail from Sigma (20 l/ml). Unbound ligand
was eliminated by centrifugation (4°C, 15 min, 20,000 × g), followed
by PBS washing and centrifugation membrane pelleting. For immu-
noblotting analysis, the membranes were solubilized by addition of
concentrated “electrophoresis sample buffer.”
Electrophoresis, Electrotransfer, and Autoradiography
The samples were analyzed by SDS-PAGE (10% acrylamide) and
the radioactivity revealed by autoradiography. Quantitative estima-
tions of the radioactivity profiles were routinely carried out by stor-
age phosphor autoradiography using a Fujix Bas 1000 apparatus.
Proteins separated by electrophoresis of solubilized membrane
preparations were transferred onto nitrocellulose membranes. Re-
ceptor detection was carried out using anti c-Myc antibodies and
the SuperSignal West Pico Chemiluminescent kit from Pierce.
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